Prognostic Value of the <scp>TLM3</scp> Biomarker Panel for Early Fibrosis Development in <scp>MASLD</scp> Within the General Population
Together, these findings indicate the potential predictive capacity of the TLM3 biomarker panel in early stages of MASLD-fibrosis, both in a murine model as well as in individuals from the general population at risk of MASLD.
Authors
- Arianne van Koppen (ORCID: https://orcid.org/0000-0001-9588-8863)
- Bert‐Jan H. van den Born (ORCID: https://orcid.org/0000-0003-0943-4393)
- Maarten E. Tushuizen (ORCID: https://orcid.org/0000-0001-6342-9056)
- Martien P. M. Caspers (ORCID: https://orcid.org/0000-0002-0248-4008)
- Quinten J. J. Augustijn (ORCID: https://orcid.org/0009-0006-9969-930X)
- Serdar Özsezen
- Anne‐Marieke van Dijk (ORCID: https://orcid.org/0000-0003-0831-527X)
- Anne Linde Mak (ORCID: https://orcid.org/0000-0002-2101-161X)
- Lars Verschuren (ORCID: https://orcid.org/0000-0002-7847-9037)
- Koen C. van Son (ORCID: https://orcid.org/0000-0001-8329-3715)
- Henrike M. Hamer (ORCID: https://orcid.org/0000-0002-6544-2331)
- Joost P.H. Drenth (ORCID: https://orcid.org/0000-0001-8027-3073)
- Adriaan Georgius Holleboom (ORCID: https://orcid.org/0000-0002-2911-2917)
- Jessica Snabel
- Roeland Hanemaaijer (ORCID: https://orcid.org/0000-0002-0408-8842)
- Jelle C. B. C. de Jong (ORCID: https://orcid.org/0000-0002-5154-4900)
- Max Nieuwdorp
- Henrike Galenkamp
- Lise Lotte Gluud (ORCID: https://orcid.org/0000-0002-9462-4468)
Institutions
- University of Copenhagen (DK)
- Loyola University Medical Center (US)
- Leiden University Medical Center (NL)
- Copenhagen University Hospital (DK)
- Amsterdam Neuroscience (NL)
- Netherlands Consortium for Healthy Ageing (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Liver International
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1111/liv.70169
- Citations
- 1
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Health~Holland
- Amsterdam University Medical Centers
- European Commission
- ZonMw
- Novo Nordisk